
Researchers have launched an EU-funded project that will investigate the diff stem cells divide

European Union - 29.02.2012

Researchers have just launched EU-funded project that will investigate the different ways embryonic stem cells divide.

When embryonic stem cells start to divide and develop into tissue, they do this through a process called differentiation. Each stem cell has the potential to differentiate into different types of tissue cells such as neurons, muscle, or blood cells, and the molecular mechanisms that determine its fate are highly complex.

The 4DCELLFATE ('Developing a global understanding of the PRC and NuRD complexes in stem cell differentiation, in health and disease') project received a





funding boost of almost EUR 12 million from the 'Health' Theme of the EU's Seventh Framework Programme (FP7). It will investigate the sophisticated and dynamic protein machineries that control the earliest steps of differentiation: polycomb repressive complex (PRC) and nucleosome remodelling and deacetylase (NuRD) complexes, which are both critical for switching genes off and on at the right time and in the right cell type.

By understanding how these complexes determine cell fate, scientists can develop models for diseases such as cancer. The models can be used both for further research and for developing personalised medicine therapies.

The project consortium brings together researchers from academia and industry in Belgium, Denmark, Germany, Spain, Italy, the Netherlands, Sweden and the United Kingdom; it comprises eight academic labs, three research-intensive small and medium-sized enterprises (SMEs) and a large pharmaceutical company.

Project coordinator Luciano Di Croce, from the Center for Genomic Regulation (CRG) in Barcelona, Spain, comments on the new project: 'This network has brought together the optimal mix of expertise, laboratories, techniques, and resources to finally elucidate how the fate of a cell is decided and how to apply this knowledge to regenerative medicine.

Together the European team will tackle the guestion of how the PRC and NuRD complexes function across space (the genome) and time (during differentiation). To find answers, they will use cutting-edge technologies such as structural biology, light microscopy, proteomics,



1 de 2

laboratory findings into new research and medical solutions, focusing on developing novel genome editing tools, refined methods for stem cell differentiation, new computational models of disease, and, ultimately, new drugs.

In addition to generating new methods and models of disease, the knowledge gained as part of the project will help scientists develop molecules that better control stem cell differentiation cultured in a dish outside the human body, or ex vivo.

Stem cells have huge potential and are a valuable source of human tissue; in the future, they could be used to generate a reliable source of tissue such as liver to study disease progression in culture. They could also be used to screen and develop drugs, allowing questions to be answered about what has gone wrong in a disease's treatment and how to improve it with small molecule drugs. Source: European Union

Related News in English

Researchers have launched an EU-funded project that will investigate the different ways embryonic stem cells divide 29.02.2012

Researchers have launched an EU-funded project that will investigate the different ways embryonic stem cells divide 29.02.2012

Romania's pharmaceuticals market remained resilient last vear

28.02.2012

Osteodensitometry laboratory put into service in Skopje, FYR Macedonia

27.02.2012

Romania's Govt. allocated from the reserve fund RON 750,000 for the urgent acquisition of drugs necessary for the treatment of cancer patients 27.02.2012

The head physician at a Turkish hospital says his team has performed the world's first quadruple limb transplant 27 02 2012

Scientists discovered a new method to clean and treat polluted water for extraction of chemicals 27.02.2012

The financial crisis forced Bulgaria's medications manufacturers to seek foreign markets 24 02 2012

The first mobile unit for screening congenital heart disease will be launched in Cyprus

24.02.2012

Wirelessly controlled microchip that would deliver drugs after implantation in a patient's body

Wirelessly controlled microchip that would deliver drugs after implantation in a patient's body 24.02.2012

Romanian drug distributor Polisano estimates its turnover rising by one fifth to EUR 356m in 2012 23.02.2012

Montenegrin Government, World Bank sign loan agreement aimed at advancing high education and science in Montenegro

Povezane vesti na srpskom

Radnicima Zastava oružja ovjerene knjižice 28.02.2012

Asteorid će iduće godine "očešati" Zemlju 28.02.2012

Zagrebu preti epidemija mišje groznice?! 27.02.2012

Jak potres na Marsu? 27.02.2012

Meksički naučnici uspješno testirali vakcinu protiv jednog od najzloglasnijih narkotika 27.02.2012

Meksički naučnici uspješno testirali vakcinu protiv jednog od najzloglasnijih narkotika 27.02.2012

Vlada Srbije pozvala radnike Zastava oružja da prekinu štrajk

24.02.2012

Smjena zbog jeftinijih lijekova u Srbiji 22.02.2012

<u>Francuzi zabranjuju pušenje na plažama</u> 21.02.2012

Francuska traži zabranu uzgoja "španskog" kukuruza 21.02.2012

Prekovremeni rad će vas uništiti 21.02.2012

Naučnici proizveli računar pametniji od 96% svjetske populacije

20.02.2012

Nova studija pokazuje da nas poslovni sastanci mogu napraviti glupima 09.02.2012

Zaštititi zdravlje radnika koji rade na otvorenom 07.02.2012

U Republici Srpskoj stopa doprinosa za zdravstveno osiguranje penzionera najniža u regionu 06.02.2012

Kompanije Actavis i Bioton formirale zajedničku kompaniju 06.02.2012

Συν

Η πρώτη μ έγινε στην 28.02.2012

Επιστήμον συνεργάζο 24.02.2012

Συνεργασί Ισραήλ και 22.02.2012

<u>Αυξήθηκαν</u> προϊόντων 21.02.2012

Μειώθηκα Κροατία το 20.02.2012

Η Krka της μετοχές 14.02.2012

Άνοιξε ο δ

<u>βρετανικο</u> 53 εκατ. ει 10.02.2012

πίσω 5.141 08.02.2012 Κρατικές ε κατασκευή

Η φαρμακ

07.02.2012 Η φαρμακ

<u>επένδυσε</u> 06.02.2012 Στη Σερβίο

ολοκληρώ τέλη του 2 03.02.2012

Η κυβέρνη των φαρμο 03.02.2012

Η GSK, η Ε

2 de 2